{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:17:37Z","timestamp":1785547057350,"version":"3.56.0"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Royal Society of New Zealand"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Global elimination of HBV is feasible thanks to the availability of a safe, effective and inexpensive vaccine. However, this will not help almost 300\u00a0million adults living with chronic HBV infection. Current therapy can reduce complications but is administered life\u2010long and is associated with risk of breakthrough and potential cumulative toxicity. There is therefore great interest in developing new therapies which can achieve sustained disease remission after a finite course of treatment i.e. an HBV CURE. Steps of HBV life cycle other than the polymerase that are targeted by new direct antiviral therapies include HBV entry, HBV capsid assembly, HBV mRNA transcription and translation and HBsAg secretion. As chronic HBV infection is characterised by high viral load and antigen burden and inadequate host immune responses innovative approaches to restore innate and adaptive immune responses against HBV, are currently in clinical development. These include therapeutic vaccines and TLR agonists. It is likely that HBV Cure will require combinations of novel immunomodulatory and antiviral approaches. In the future, strategies which directly silence or eliminate cccDNA could provide a single agent cure. Efficacy, safety, route of administration and cost will ultimately determine the impact of these new regimens on the burden of HBV.<\/jats:p>","DOI":"10.1080\/03036758.2020.1811355","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T18:50:31Z","timestamp":1602787831000},"page":"129-148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["The roadmap towards cure of chronic hepatitis B virus infection"],"prefix":"10.1002","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-7955","authenticated-orcid":false,"given":"Edward","family":"Gane","sequence":"first","affiliation":[{"name":"Department of Medicine Faculty of Medical and Health Sciences The University of Auckland Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12942"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112754"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.044"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104853"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.011"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011\u2010010\u20100233\u20101"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.01.010"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(17)31859\u20107"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.027"},{"key":"e_1_2_17_12_1","unstructured":"GaneE.2020.Study of VIR\u20103434\u00a0in healthy volunteers and patients with chronic hepatitis B virus infection.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04423393."},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30964\u20108"},{"issue":"1","key":"e_1_2_17_14_1","first-page":"435A","article-title":"Dose response with the RNA interference therapy JNJ\u20103989 combined with nucleos(t)ide analogue treatment in Expanded Cohorts of patients with chronic hepatitis B","volume":"70","author":"Gane E","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"e_1_2_17_15_1","first-page":"1279A","article-title":"Phase 1a trial of the first HBV core inhibitor: safety and pharmacokinetics of NVR 3\u2010778","volume":"60","author":"Gane E","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"issue":"1","key":"e_1_2_17_17_1","first-page":"436A","article-title":"Interim results of a phase 1 study of RO7062931, a novel liver\u2010targeted single\u2010stranded oligonucleotide (SSO) with locked nucleic acid (LNA) that targets HBV transcripts","volume":"70","author":"Gane E","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_17_18_1","first-page":"435A","article-title":"Efficacy and safety of oral TLR8 agonist GS\u20109688\u00a0in virally suppressed adult patients with chronic hepatitis B: a phase 2, randomized, double\u2010blind, placebo\u2010controlled, multicenter study","volume":"70","author":"Gane E","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201048826\u20106"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)61682\u20102"},{"key":"e_1_2_17_21_1","unstructured":"Global Health Sector Strategy on viral hepatitis 2016\u20132021.2016.Geneva: WHO.[accessed 2018 Aug 10].http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO\u2010HIV\u20102016.06\u2010eng.pdf."},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30085\u20104"},{"key":"e_1_2_17_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318792537"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.027"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.038893"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1513803112"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30230-0"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.09.038"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003856"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.003"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.016"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.026"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30329"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230601"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(16)30204\u20103"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.024"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(01)00028\u20109"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(18)30056\u20106"},{"issue":"3","key":"e_1_2_17_39_1","first-page":"215","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann B","year":"2005","journal-title":"Nature Reviews"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00764"},{"key":"e_1_2_17_41_1","unstructured":"Spring Bank Pharmaceuticals Inc.2020.Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV.Hopkinton Massachusetts; [accessed 2020 Aug 5].https:\/\/ir.springbankpharm.com\/news\u2010releases\/news\u2010release\u2010details\/spring\u2010bank\u2010discontinues\u2010development\u2010inarigivir\u2010treatment\u2010hbv?field_nir_news_date_value[min]%3D."},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21702"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810477"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(02)00345\u20106"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.030"},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.072"},{"key":"e_1_2_17_47_1","doi-asserted-by":"crossref","unstructured":"WangJ ChenR ZhangR DingS ZhangT YuanQ GuanG ChenX ZhangT ZhuangH et al.2017.Dual\u2010gRNAs and gRNA\u2010microRNA (miRNA)\u2010gRNA ternary cassette combined CRISPR\/Cas9 system and RNAi approach promotes the clearance of HBV cccDNA.Theranostics. 7(12):3090\u20133105.","DOI":"10.7150\/thno.18114"},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22295"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.003"},{"key":"e_1_2_17_50_1","unstructured":"WHO 2017 Global Hepatitis Report. [accessed 2018 Aug 10].http:\/\/www.who.int\/hepatitis\/publications\/global\u2010hepatitis\u2010report2017\/en\/."},{"key":"e_1_2_17_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"e_1_2_17_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(16)00626\u20107"},{"issue":"6","key":"e_1_2_17_53_1","first-page":"1477A","article-title":"Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB\u2010506\u00a0in healthy subjects (HS) and chronic hepatitis B (CHB) subjects","volume":"70","author":"Yuen M","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(16)00606\u20101"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30084\u20102"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.023"},{"issue":"1","key":"e_1_2_17_57_1","first-page":"437A","article-title":"Phase 2a, randomized, double\u2010blind, placebo\u2010controlled study of an antisense inhibitor (ISIS 505358) in treatment\u2010naive CHB patients: safety and antiviral efficacy","volume":"70","author":"Yuen M\u2010F","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30851\u20105"},{"key":"e_1_2_17_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)31437\u20109"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30847\u20103"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618\u20108278(19)30174\u20104"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.036"}],"container-title":["Journal of the Royal Society of New Zealand"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rsnz.onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/03036758.2020.1811355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/rsnz.onlinelibrary.wiley.com\/doi\/full-xml\/10.1080\/03036758.2020.1811355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/rsnz.onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/03036758.2020.1811355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T14:16:32Z","timestamp":1769350592000},"score":1,"resource":{"primary":{"URL":"https:\/\/rsnz.onlinelibrary.wiley.com\/doi\/10.1080\/03036758.2020.1811355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1080\/03036758.2020.1811355"],"URL":"https:\/\/doi.org\/10.1080\/03036758.2020.1811355","archive":["Portico"],"relation":{},"ISSN":["0303-6758","1175-8899"],"issn-type":[{"value":"0303-6758","type":"print"},{"value":"1175-8899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tnzr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tnzr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}